ATE413173T1 - Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung - Google Patents

Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung

Info

Publication number
ATE413173T1
ATE413173T1 AT05816322T AT05816322T ATE413173T1 AT E413173 T1 ATE413173 T1 AT E413173T1 AT 05816322 T AT05816322 T AT 05816322T AT 05816322 T AT05816322 T AT 05816322T AT E413173 T1 ATE413173 T1 AT E413173T1
Authority
AT
Austria
Prior art keywords
inhibition
serotonin
reuppost
combination
phenylpiperazine derivatives
Prior art date
Application number
AT05816322T
Other languages
German (de)
English (en)
Inventor
Roelof W Feenstra
Axel Stoit
Jan-Willem Terpstra
Maria L Pras-Raves
Andrew C Mccreary
Vliet Bernard Van
Mayke Hesselink
Cornelis Kruse
Scharrenburg G J M Van
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of ATE413173T1 publication Critical patent/ATE413173T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05816322T 2004-12-08 2005-12-06 Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung ATE413173T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63407404P 2004-12-08 2004-12-08
EP04106394 2004-12-08

Publications (1)

Publication Number Publication Date
ATE413173T1 true ATE413173T1 (de) 2008-11-15

Family

ID=35744728

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05816322T ATE413173T1 (de) 2004-12-08 2005-12-06 Phenylpiperazin-derivate mit einer kombination aus teilweisem dopamin-d2-rezeptor-agonismus und serotonin-wiederaufnahmehemmung
AT05850037T ATE401883T1 (de) 2004-12-08 2005-12-06 Aryloxyethylaminderivate mit einer kombination aus partiellem dopamin-d2-rezeptoragonismus und serotonin-wiederaufnahmehemmung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05850037T ATE401883T1 (de) 2004-12-08 2005-12-06 Aryloxyethylaminderivate mit einer kombination aus partiellem dopamin-d2-rezeptoragonismus und serotonin-wiederaufnahmehemmung

Country Status (18)

Country Link
EP (4) EP1824479B1 (https=)
JP (4) JP2008523031A (https=)
KR (4) KR20070085988A (https=)
AT (2) ATE413173T1 (https=)
AU (4) AU2005313311A1 (https=)
BR (1) BRPI0518613A2 (https=)
CA (4) CA2587559A1 (https=)
DE (2) DE602005008471D1 (https=)
DK (2) DK1827427T3 (https=)
ES (2) ES2311245T3 (https=)
HR (2) HRP20080538T3 (https=)
IL (4) IL183061A0 (https=)
NO (4) NO20072974L (https=)
PL (2) PL1824479T3 (https=)
PT (2) PT1824479E (https=)
RU (4) RU2007125659A (https=)
SI (2) SI1824479T1 (https=)
WO (4) WO2006061376A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525304A (ja) * 2006-01-30 2009-07-09 シュペーデル・エクスペリメンタ・アーゲー α,β−不飽和化合物からのアルコールの立体選択的製造方法
US8063062B2 (en) 2006-12-20 2011-11-22 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
EP2111394A1 (en) * 2007-01-10 2009-10-28 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
US8138174B2 (en) 2007-01-10 2012-03-20 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
RS52518B (sr) * 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
MX2009011416A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
US20100137368A1 (en) * 2007-04-23 2010-06-03 Janssen Pharmaceutica N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
CN103360342B (zh) * 2012-04-09 2015-12-16 江苏恩华药业股份有限公司 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
ITMI20130392A1 (it) * 2013-03-15 2014-09-16 Dipharma Francis Srl Sintesi di un inibitore della ricaptazione della serotonina
WO2014203217A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
WO2014207648A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
JP2002510675A (ja) * 1998-04-08 2002-04-09 アメリカン・ホーム・プロダクツ・コーポレイション うつ病治療用のn−アリールオキシエチル−インドリル−アルキルアミン(5−ht1a受容体活性薬)
HUP0101475A3 (en) * 1998-06-19 2003-01-28 Lundbeck & Co As H 4,5,6 and 7-indole and indoline derivatives, their preparation and use
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
WO2001014330A2 (en) * 1999-08-23 2001-03-01 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
BR0317126A (pt) * 2002-12-10 2005-10-25 Merck Patent Gmbh Derivados de indol e o uso dos mesmos como ligantes de 5-ht

Also Published As

Publication number Publication date
WO2006061378A1 (en) 2006-06-15
EP1827427A1 (en) 2007-09-05
NO20072974L (no) 2007-08-23
JP2008523029A (ja) 2008-07-03
SI1827427T1 (sl) 2008-12-31
KR20070085916A (ko) 2007-08-27
RU2007125658A (ru) 2009-01-20
RU2007125661A (ru) 2009-01-20
CA2587202A1 (en) 2006-06-15
BRPI0518613A2 (pt) 2008-11-25
AU2005313391A1 (en) 2006-06-15
ES2311245T3 (es) 2009-02-01
EP1824480A1 (en) 2007-08-29
PT1827427E (pt) 2008-11-03
CA2587357A1 (en) 2006-06-15
HRP20080538T3 (en) 2008-12-31
AU2005313390A1 (en) 2006-06-15
IL183064A0 (en) 2007-09-20
JP2008523031A (ja) 2008-07-03
DK1827427T3 (da) 2008-11-24
KR20070085988A (ko) 2007-08-27
EP1824479B1 (en) 2008-11-05
NO20072981L (no) 2007-09-05
IL183061A0 (en) 2007-09-20
JP2008523030A (ja) 2008-07-03
DE602005010902D1 (de) 2008-12-18
HRP20090015T3 (en) 2009-02-28
DK1824479T3 (da) 2009-03-09
IL183062A0 (en) 2007-09-20
CA2587559A1 (en) 2006-06-15
RU2007125659A (ru) 2009-01-20
PL1827427T3 (pl) 2009-01-30
RU2007125660A (ru) 2009-01-20
ATE401883T1 (de) 2008-08-15
PL1824479T3 (pl) 2009-04-30
EP1827427B1 (en) 2008-07-23
PT1824479E (pt) 2009-01-30
WO2006061376A1 (en) 2006-06-15
NO20072969L (no) 2007-08-31
JP2008537725A (ja) 2008-09-25
WO2006061379A1 (en) 2006-06-15
AU2005313312A1 (en) 2006-06-15
EP1824479A1 (en) 2007-08-29
AU2005313311A1 (en) 2006-06-15
KR20070085975A (ko) 2007-08-27
CA2587381A1 (en) 2006-06-15
NO20072977L (no) 2007-09-05
EP1827426A1 (en) 2007-09-05
IL183063A0 (en) 2007-09-20
WO2006061377A1 (en) 2006-06-15
SI1824479T1 (sl) 2009-04-30
KR20070085959A (ko) 2007-08-27
DE602005008471D1 (de) 2008-09-04
ES2317335T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
IL183061A0 (en) Aryloxyethylamine derivatives with a combination of partial dopamine d2 receptor agonism and serotonin reuptake inhibition
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
PE20081690A1 (es) Sal de tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma
ATE493386T1 (de) Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CR11169A (es) Oxazolidinonas sustituidas y su uso
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
DK2227476T3 (da) Tricykliske triazoliske forbindelser
CR11463A (es) Compuestos de piridilmetil-sulfonamida
MX2009003713A (es) Inhibidor de progresion de enfermedad de alzheimer que contiene un compuesto heterociclico con estructura especifica.
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
ECSP109874A (es) Nuevos compuestos 892
TW200634009A (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
TW200633987A (en) Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
UY31668A1 (es) "ligando de receptor d2-078"
EA200970710A1 (ru) ПРОИЗВОДНЫЕ 2-ПИПЕРАЗИН-1-ИЛ-3Н-ИМИДАЗО[4,5-b]ПИРИДИНА
NO20073390L (no) Fenylpiperaziner med en kombinasjon av affinitet for dopamin-D2-reseptorer og serotoningjenopptaksseter
ATE538662T1 (de) Bicyclische campholenderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1824479

Country of ref document: EP

REN Ceased due to non-payment of the annual fee